Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Cancer Research Foundation CR | UNKNOWN |
Not provided
Not provided
Not provided
Not provided
The trial will evaluate if the newly identified biomarkers of lung cancer in exhaled breath condensate are as a diagnostic tool comparable to the low-dose computer tomography (LDCT) implemented in lung cancer screening recently. Due to the possibility to collect breath condensate at any medical workplace and due to the relatively low financial cost of examination of the collected breath condensate could improve early diagnosis of lung cancer, differential diagnostics of lung nodules and thereby reduce both the unnecessary interventions and deaths from this type of cancer.
The project aims to validate newly identified biomarkers of lung cancer in breath condensate for the diagnosis and triage of lung nodules (malignant versus benign), further set the mechanisms of the functioning of the lung cancer screening center, validate the quality indicators of LDCT screening for the Czech Republic and stratify the cohort of individuals so that optimized output of screening activities. Patients aged 55-74 years with a heavy smoking load (more than 20, preferably more than 30 pack/years) will be divided into risk groups according to biomarkers in exhaled air, clinical/anamnesis data and the degree of obstructive ventilation disorder according to spirometry and subsequently there will be effective stratification of the risk of lung carcinoma. The group with the highest risk of developing lung cancer will then be diagnosed with early lung cancer using ultra-low-dose computed tomography of the chest. This will lead to early diagnosis and subsequently to a reduction in the mortality rate of the monitored active group compared to the historical cohort. The primary outcome will be the validation of the multiplex protein signature in exhaled air, the effectiveness of the screening procedure to reduce lung cancer mortality and overall mortality in the group with FEV1 (forced expiratory volume at 1 second) pre-bronchodilation 60-75% with the entire group of examinees. The secondary outcome will then be the total time of diagnosis of a solitary pulmonary nodule in positively screened patients for whom only observation is not a sufficient procedure. Another secondary outcome will be the costs of screening procedures for individual groups and the percentage of success of the anti-smoking intervention for the enrolled individuals. The number of newly captured interstitial lung processes will also be evaluated. Patients will be evaluated for 5 years at annual visits or earlier based on their LDCT result.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| LDCT and collection of breath condensate and blood sample | Experimental | Each participant of the study will provide exhaled breath condensate sample and blood sample for further laboratory analyses. Each participant will have LDCT (low dose computer tomography) performed. A pulmonologist examines the patient for any concomitant diseases and performs spirometry. Vital signs will be measured. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Exhaled breath condensate sampling | Diagnostic Test | Patient will breath for approx. 10 minutes to a breath condenser. The exhaled breath sample will be condensed and freezed. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Validation of the multiplex protein signature in exhaled air | Validation of the multiplex protein signature in exhaled breath condensate based on the comparison with the LDCT. | 5 years |
| Validation of the multiplex protein signature in exhaled breath for differential diagnostics of lung nodules | Validation of the multiplex protein signature in exhaled breath for differential diagnostics of lung nodules | 5 years |
| Assessment of the effectiveness of the screening program | Assesment of the effectiveness of the screening procedure to reduce lung cancer mortality and overall mortality in the group with FEV1 (forced expiratory volume at 1 second) pre-bronchodilation 60-75% compared with the entire group of examinees. | 5 years |
| Measure | Description | Time Frame |
|---|---|---|
| Total time of diagnosis of the nodule | The total time of diagnosis of a solitary pulmonary nodule in positively screened patients for whom only observation is not a sufficient procedure. | 5 years |
| Comparison of costs of screening procedures |
| Measure | Description | Time Frame |
|---|---|---|
| Number of newly captured interstitial lung processes | The number of newly captured interstitial lung processes will also be evaluated. | 5 years |
Inclusion Criteria:
Consent to participate in a clinical trial.
A clients within an age of 55-74 years.
Current smoker or ex-smoker who has smoked at least 20 pack-years, provided that:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Marian Hajduch, MD, PhD. | Contact | +420 585632083 | marian.hajduch@upol.cz | |
| Michaela Bendova, MSc. | Contact | +420585632050 | michaela.bendova@upol.cz |
| Name | Affiliation | Role |
|---|---|---|
| Marian Hajduch, MD, PhD. | IMTM, Palacky University in Olomouc, Faculty of Medicine and Dentistry | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Masaryk Memorial Cancer Institute | Recruiting | Brno | 65653 | Czechia |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Blood sampling | Diagnostic Test | A venous blood sample will be taken for further biomarker analysis. |
|
| LDCT | Procedure | LDCT scan will be performed. |
|
|
| Vital signs | Diagnostic Test | Blood pressure, weight, height, pulse, oxygen saturation will be measured. |
|
| Spirometry | Diagnostic Test | Spirometry will be performed. |
|
Comparison of the costs of the screening procedures for exhaled breath condensate sample and LDCT procedure. This will be asssessed based on the individula patient data: total screening costs per patient from Healthcare registry in Czech Republic.
| 5 years |
| Assessment of success of the anti-smoking intervention | Percentage success of the anti-smoking intervention in the examined probands. | 5 years |
| University Hospital | Not yet recruiting | Olomouc | 77900 | Czechia |
|
| General University Hospital in Prague | Not yet recruiting | Prague | 12808 | Czechia |
|
| ID | Term |
|---|---|
| D008175 | Lung Neoplasms |
| ID | Term |
|---|---|
| D012142 | Respiratory Tract Neoplasms |
| D013899 | Thoracic Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D001800 | Blood Specimen Collection |
| D055986 | Vital Signs |
| D013147 | Spirometry |
| ID | Term |
|---|---|
| D013048 | Specimen Handling |
| D019411 | Clinical Laboratory Techniques |
| D019937 | Diagnostic Techniques and Procedures |
| D003933 | Diagnosis |
| D011677 | Punctures |
| D013514 | Surgical Procedures, Operative |
| D008919 | Investigative Techniques |
| D010808 | Physical Examination |
| D012129 | Respiratory Function Tests |
| D003948 | Diagnostic Techniques, Respiratory System |
Not provided
Not provided